Semaglutide and tirzepatide in patients with heart failure with preserved ejection fraction

JAMA

2025-08-31

(Press-News.org) About The Study: In patients with cardiometabolic heart failure with preserved ejection fraction, semaglutide and tirzepatide showed more than 40% risk reduction for the composite of hospitalization for heart failure or all-cause mortality compared with a placebo proxy. Tirzepatide showed no meaningful benefit over semaglutide.

Corresponding Author: To contact the corresponding author, Nils Krüger, MD, email nkruger1@bwh.harvard.edu.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.14092?guestAccessKey=604055a2-ce86-4984-8c53-11e9184281a1&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=083125

END

ELSE PRESS RELEASES FROM THIS DATE:

Changes in biology of internal fat may be the leading cause of heart failure

2025-08-31

Heart failure with preserved ejection fraction (HFpEF) appears to develop as a result of changes in the biology of a person’s internal fat tissue, according to the Adipokine Hypothesis, a new way of understanding how fat may impact the heart. The hypothesis paper was published today in JACC, the flagship journal of the American College of Cardiology, and is being presented at ESC Congress 2025. The author of the paper is Milton Packer, MD, FACC, Distinguished Scholar in Cardiovascular Science at Baylor University Medical Center at Dallas and Visiting Professor at Imperial College in London. “Up ...

Transcatheter or surgical treatment of patients with aortic stenosis at low to intermediate risk

2025-08-30

About The Study: In this individual participant data meta-analysis of 4 randomized clinical trials (RCTs), and an overall meta-analysis of 8 RCTs of patients with severe symptomatic aortic stenosis at low to intermediate risk, transcatheter aortic valve implantation (TAVI) was associated with a reduction in the 1-year incidence of all-cause death or any stroke. These findings emphasize TAVI as alternative option in patients at low to intermediate risk. Long-term follow-up is warranted to evaluate sustainability of these findings. Corresponding Authors: To contact the corresponding authors, email Moritz Seiffert, MD, (moritz.seiffert@bergmannsheil.de) and ...

Promising new drug for people with stubborn high blood pressure

2025-08-30

A new treatment has been shown to significantly lower blood pressure in people whose levels stay dangerously high, despite taking several existing medicines, according to the results of a Phase III clinical trial led by a UCL Professor. Globally around 1.3 billion people have high blood pressure (hypertension), and in around half of cases the condition is uncontrolled or treatment resistant. These individuals face a much greater risk of heart attack, stroke, kidney disease, and early death. In the UK the number of people with hypertension is around 14 ...

One shot of RSV vaccine effective against hospitalization in older adults for two seasons

2025-08-30

One shot of an RSV vaccine protects adults ages 60 or older from RSV-associated hospitalization and critical illness during two consecutive RSV seasons, according to a study published in JAMA today by the IVY Network research group. RSV causes substantial seasonal illness during fall and winter in the U.S., with an estimated 100,000-150,000 hospitalizations and 4,000-8,000 deaths occurring annually among adults 60 or older. The results reinforce the recommendations for RSV vaccines in older adults and lay the groundwork for understanding how long a single dose of the vaccine may be effective, ...

Bivalent RSV prefusion F protein–based vaccine for preventing cardiovascular hospitalizations in older adults

2025-08-30

About The Study: In adults age 60 or older, all-cause cardiorespiratory hospitalization was significantly lower with respiratory syncytial virus (RSV) prefusion F protein than with no vaccine. The findings suggest potential downstream cardiorespiratory benefits of RSV immunization, although the effect on all-cause cardiovascular hospitalization was not statistically significant. Corresponding Author: To contact the corresponding author, Tor Biering-Sørensen, MD, MSc, MPH, PhD, email tor.biering@gmail.com. To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ Editor’s ...

Clonal hematopoiesis and risk of new-onset myocarditis and pericarditis

2025-08-30

About The Study: In this study, clonal hematopoiesis of indeterminate potential (CHIP) was a strong risk factor for myocarditis and pericarditis among middle-aged adults. Targeting CHIP and its downstream pathways may represent a strategy for preventing or treating pericarditis and myocarditis. Corresponding Author: To contact the corresponding author, Michael C. Honigberg, MD, MPP, email mhonigberg@mgh.harvard.edu. To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ Editor’s Note: Please see the article for additional information, including other authors, author contributions ...

Risk of myocarditis or pericarditis with high-dose vs standard-dose influenza vaccine

2025-08-30

About The Study: In this prespecified analysis of the DANFLU-2 trial, the risk of incident myocarditis or pericarditis was lower among individuals randomized to high-dose inactivated influenza vaccine vs standard-dose- inactivated influenza vaccine. Despite sporadic reports of myocarditis and pericarditis associated with influenza vaccination, the consistency of our results with vs without inclusion of events occurring immediately after vaccination negates a dose-response association and a causal link. Corresponding Author: To ...

High-dose vs standard-dose influenza vaccine and cardiovascular outcomes in older adults

2025-08-30

About The Study: This study found reduced incidence of cardiorespiratory hospitalization among those who received high-dose inactivated influenza vaccine vs standard-dose inactivated influenza vaccine, driven by a lower incidence of cardiovascular hospitalizations, and particularly heart failure hospitalizations. These differences should be interpreted as exploratory findings in the setting of a large randomized clinical trial with a neutral primary outcome. Corresponding Author: To contact the corresponding author, Tor Biering-Sørensen, ...

Prevalence, determinants, and time trends of cardiovascular health in the WHO African region

2025-08-30

About The Study: This situational analysis of cross-sectional WHO STEPS surveys of cardiovascular health (CVH) status region identified actionable factors of the CVH status across 22 countries in the WHO African Region. This information is crucial for guiding policy efforts in cardiovascular disease prevention in countries of the WHO African Region. Corresponding Author: To contact the corresponding author, Jean-Philippe Empana, MD, PhD, email jean-philippe.empana@inserm.fr. To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ Editor’s Note: Please see the article for additional information, including ...

New study finds that, after a heart attack, women have worse prognosis when treated with beta-blockers

2025-08-30

A major new analysis from REBOOT (Treatment with Beta-blockers after Myocardial Infarction without Reduced Ejection Fraction) clinical trial, an international study coordinated by the Centro Nacional de Investigaciones Cardiovasculares (CNIC), published at the European Heart Journal has revealed important sex-specific differences in the effects of beta-blockers following heart attacks, raising questions about long-standing treatment practices. REBOOT, presented in a Hotline session of the ESC congress in Madrid, ...

Semaglutide and tirzepatide in patients with heart failure with preserved ejection fraction

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: